CompletedPHASE1, PHASE2NCT03331341

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Studying Hodgkin lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Washington
Principal Investigator
Ryan Lynch
Fred Hutch/University of Washington Cancer Consortium
Intervention
Dacarbazine(drug)
Enrollment
50 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03331341 on ClinicalTrials.gov

Other trials for Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Hodgkin lymphoma →

← Back to all trials